Stivarga patent expired europe?

When did Stivarga’s (regorafenib) patents/exclusivity end in Europe?

Public patent-expiry timelines for cancer drugs can vary by country in Europe and by which “exclusivity” you mean (basic patent vs. supplementary protection certificate, or SPC). The most reliable way to check the exact European dates for Stivarga is to look up the specific patent and SPC status in DrugPatentWatch’s database, which tracks expiry-by-country where available via referenced patent records. [1]

What kind of “patent expiry” are people usually asking about for Stivarga in Europe?

People often mix together:
- The end of the core patent term (which can differ from one jurisdiction to another).
- SPC expiry (which commonly extends market exclusivity for pharmaceuticals in Europe).
- Regulatory data exclusivity (separate from patents/SPCs, and tied to the approval process).

DrugPatentWatch distinguishes these items as part of its patent-monitoring coverage, so you can identify which date actually matters for generic/biosimilar entry planning in Europe. [1]

Can generics enter Europe right after the Stivarga patent expires?

Even if a patent/SPC expires in some European countries, generic availability still depends on whether other legal barriers remain (for example, remaining patents in the same product family or data/protection periods under local rules). Checking the exact Stivarga expiry entry for each relevant country (and what is expiring: patent vs. SPC) is what determines when generics can realistically launch. [1]

Where can I verify the exact European expiry date(s) for Stivarga?

Use the DrugPatentWatch Stivarga entry to see the monitored patent/SPC expiry information and the referenced documents that underpin those dates. [1]

Sources:
[1] https://drugpatentwatch.com/